Sort   by:  
 Page size 
UnknownBortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502.
Not available
S-EPMC3577952 | biostudies-literature
UnknownCPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia.
Not available
S-EPMC6127025 | biostudies-literature
UnknownClinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients.
Not available
S-EPMC3731981 | biostudies-literature
UnknownAge-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia.
Not available
S-EPMC3295550 | biostudies-literature
UnknownPrognostic significance of the European LeukemiaNet standardized system for reporting cytogenetic and molecular alterations in adults with acute myeloid leukemia.
Not available
S-EPMC3518729 | biostudies-literature
UnknownEpigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene score.
Not available
S-EPMC3918538 | biostudies-literature
Sort   by:  
 Page size